Maze Therapeutics CMO exercises options, sells 15K shares

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options to acquire 15,000 shares of common stock at $10.42 per share.

Accepted by SEC EDGAR 03/20/2026 - 06:50 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options to acquire 15,000 shares of common stock at $10.42 per share. On the same day, he sold those 15,000 shares in open-market transactions at weighted average prices between $47.77 and $50.52 per share. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating a scheduled liquidity event rather than a discretionary trade.

Insider Trade Summary 10b5-1

Exercise and Sale: 15,000 shares ($580K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Bernstein Harold

Role President, R&D & CMO

Sold 15,000 shs ($736K)

Approx. gross sale proceeds $736K

Approx. exercise cost $156K

Approx. pre-tax spread $580K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$10.42	$156K
Sale	Common Stock	6,161	$48.2027	$297K
Sale	Common Stock	3,795	$49.3198	$187K
Sale	Common Stock	5,044	$50.0186	$252K

Holdings After Transaction: Stock Option (Right to Buy) — 252,407 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (5)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.77 to $48.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.78 to $49.77 per share, inclusive.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.79 to $50.52 per share, inclusive.
5. F5. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Maze Therapeutics (MAZE) executive Harold Bernstein report on this Form 4?

Harold Bernstein reported exercising stock options for 15,000 Maze Therapeutics shares at $10.42 each and selling those 15,000 shares in the open market. The trades occurred on March 20, 2026 and were executed under a pre-set Rule 10b5-1 trading plan.

How many Maze Therapeutics (MAZE) shares did Harold Bernstein sell and at what prices?

He sold a total of 15,000 common shares of Maze Therapeutics in three open-market tranches. The weighted average sale prices ranged from $47.77 to $50.52 per share, with specific weighted averages reported around the $48–$50 range in the Form 4.

Were Harold Bernstein’s Maze Therapeutics (MAZE) stock sales part of a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025. Such plans pre-schedule trades, meaning the timing of these sales was set in advance rather than decided on the trade date.

What options did Harold Bernstein exercise for Maze Therapeutics (MAZE) stock?

He exercised a stock option covering 15,000 shares of Maze Therapeutics common stock at an exercise price of $10.42 per share. The option originally vested over time, with a quarter vesting on October 3, 2023 and the remainder vesting monthly thereafter.

Is Harold Bernstein’s Form 4 transaction a buy or sell signal for Maze Therapeutics (MAZE)?

The filing shows an exercise-and-sell pattern: options were exercised to obtain 15,000 shares, then all 15,000 shares were sold. Because the trades occurred under a Rule 10b5-1 plan, they appear as planned liquidity rather than a spontaneous market-timing decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		M(1)		15,000	A	$10.42	15,000	D
Common Stock	03/20/2026		S(1)		6,161	D	$48.2027(2)	8,839	D
Common Stock	03/20/2026		S(1)		3,795	D	$49.3198(3)	5,044	D
Common Stock	03/20/2026		S(1)		5,044	D	$50.0186(4)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	03/20/2026		M(1)			15,000	(5)	10/26/2032	Common Stock	15,000	$0	252,407	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.77 to $48.75 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.78 to $49.77 per share, inclusive.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.79 to $50.52 per share, inclusive.

5. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)